Emilie M. Gieling

Mortality risk in atrial fibrillation: the role of aspirin, vitamin K and non-vitamin K antagonists

A. de Boer, Rachael Williams, F. de Vries, 2019, International Journal of Clinical Pharmacy.

Higher Dosage of Ciprofloxacin Necessary in Critically Ill Patients: A New Dosing Algorithm Based on Renal Function and Pathogen Susceptibility

D. D. de Lange, P. Pickkers, J. ten Oever, 2020, Clinical pharmacology and therapeutics.

Pooled Population Pharmacokinetic Analysis for Exploring Ciprofloxacin Pharmacokinetic Variability in Intensive Care Patients

D. D. de Lange, H. Endeman, A. Dijkstra, 2022, Clinical Pharmacokinetics.

Risk of major bleeding and stroke associated with the use of vitamin K antagonists, nonvitamin K antagonist oral anticoagulants and aspirin in patients with atrial fibrillation: a cohort study

A. de Boer, F. de Vries, A. Burden, 2017, British journal of clinical pharmacology.

High unbound flucloxacillin fraction in critically ill patients

D. D. de Lange, P. Pickkers, J. ten Oever, 2021, The Journal of antimicrobial chemotherapy.